Tech Company Financing Transactions
ViaCyte Funding Round
On 5/24/2017, ViaCyte received $10 million in funding from Asset Management Ventures, JDRF T1D Fund and W.L. Gore & Associates.
Transaction Overview
Company Name
Announced On
5/24/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Proceeds Purpose
This capital will be used to fund the initiation of clinical development for ViaCyte's PEC-Direct product candidate, which holds the promise of becoming a functional cure for type 1 diabetes patients at high risk for acute complications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3550 General Atomics Ct.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Yang
Chief Financial Officer
Brittany Bradrick
Chief Medical Officer
Howard Foyt
Chief Scientific Officer
Kevin D'Amour
Chief Technical Officer
Steve White
Vice President
Manasi Jaiman
VP - Finance
Anne Sandan
VP - General Counsel
Liz Bui
VP - Regulatory Affairs
Steve Kradjian
Browse more venture capital transactions:
Prev: 5/23/2017: LumaStream venture capital transaction
Next: 5/24/2017: Minibrew venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs